Cargando…

Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy

Histone deacetylase inhibitors (HDACi) can induce human immunodeficiency virus (HIV) transcription from the HIV long terminal repeat (LTR). However, ex vivo and in vivo responses to HDACi are variable and the activity of HDACi in cells other than T-cells have not been well characterised. Here, we de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Hao K., Gray, Lachlan R., Wightman, Fiona, Ellenberg, Paula, Khoury, Gabriela, Cheng, Wan-Jung, Mota, Talia M., Wesselingh, Steve, Gorry, Paul R., Cameron, Paul U., Churchill, Melissa J., Lewin, Sharon R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237424/ https://www.ncbi.nlm.nih.gov/pubmed/25409334 http://dx.doi.org/10.1371/journal.pone.0113341

Ejemplares similares

Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus
por: Churchill, Melissa J, et al.
Publicado: (2007)

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
por: Borm, Katharina, et al.
Publicado: (2016)

Macrophage Tropism and Cytopathicity of HIV-1 Variants Isolated Sequentially from a Long-Term Survivor Infected with nef-Deleted Virus
por: Gorry, Paul R, et al.
Publicado: (2007)

Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues
por: Gray, Lachlan, et al.
Publicado: (2011)

HIV-1 Entry and Trans-Infection of Astrocytes Involves CD81 Vesicles
por: Gray, Lachlan R., et al.
Publicado: (2014)

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies
por: Gray, L R, et al.
Publicado: (2016)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors
por: Smith, Johanna A, et al.
Publicado: (2010)

Persistence of envelopes in different CD4(+) T-cell subsets in antiretroviral therapy-suppressed people with HIV
por: Gartner, Matthew J., et al.
Publicado: (2023)

Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source
por: Gray, Lachlan, et al.
Publicado: (2007)

HIV UTR, LTR, and Epigenetic Immunity
por: Zhang, Jielin, et al.
Publicado: (2022)

CoRSeq(V3-C): a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm
por: Cashin, Kieran, et al.
Publicado: (2013)

Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency
por: Hurst, Tara, et al.
Publicado: (2016)

Measuring and monitoring apoptosis and drug toxicity in HIV patients by ligation-mediated polymerase chain reaction
por: Hooker, David J, et al.
Publicado: (2009)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
por: Gorry, Paul R, et al.
Publicado: (2007)

GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy
por: Gubser, Céline, et al.
Publicado: (2023)

HIV 2-LTR experiment design optimization
por: Cannon, LaMont, et al.
Publicado: (2018)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy
por: White, Jennifer A., et al.
Publicado: (2022)

Designer antigens for elicitation of broadly neutralizing antibodies against HIV
por: Kok, Tuckweng, et al.
Publicado: (2014)

Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy
por: Zhu, Weijun, et al.
Publicado: (2011)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro
por: Anderson, Jenny L., et al.
Publicado: (2016)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans
por: Herrera, Carolina, et al.
Publicado: (2022)

Understanding the mechanisms driving the spread of subtype C HIV-1
por: Gartner, Matthew J., et al.
Publicado: (2020)

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells
por: Saleh, Suha, et al.
Publicado: (2011)

Transcriptional modulation of HIV-1C LTR promoter
por: Singh, Anand, et al.
Publicado: (2012)

New transcription regulatory mechanisms of latent HIV LTR
por: Rafati, Haleh, et al.
Publicado: (2012)

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
por: Sterjovski, Jasminka, et al.
Publicado: (2007)

Longitudinal analysis of subtype C envelope tropism for memory CD4(+) T cell subsets over the first 3 years of untreated HIV-1 infection
por: Gartner, Matthew J., et al.
Publicado: (2020)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d68fjuhj51gbifilugu17l1u2h